Compounds > dacarbazine

dacarbazine and Colonic Inertia

dacarbazine has been researched along with Colonic Inertia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amatu, A; Belotti, A; Bencardino, K; Cassingena, A; Chirico, G; Esposito, A; Esteller, M; Moutinho, C; Nichelatti, M; Rusconi, F; Sartore-Bianchi, A; Siena, S1
Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY1
Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y1
Bertorelle, R; Biscuola, M; Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Ermani, M; Franceschi, E; Gioia, V; Tosoni, A1

Trials

4 trial(s) available for dacarbazine and Colonic Inertia

ArticleYear
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Constipation; CpG Islands; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Prognosis; Promoter Regions, Genetic; Treatment Outcome; Tumor Suppressor Proteins

2013
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Cancer, 2016, Feb-15, Volume: 122, Issue:4

    Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Constipation; Dacarbazine; Diarrhea; Fatigue; Female; Glioblastoma; Humans; Hypertension; L-Lactate Dehydrogenase; Leukopenia; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Grading; Neurosurgical Procedures; Neutropenia; Pyridines; Temozolomide; Thrombocytopenia; Treatment Outcome

2016
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4

    Topics: Administration, Oral; Adult; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Central Nervous System Neoplasms; Constipation; Cross-Over Studies; Dacarbazine; Drug Administration Schedule; Female; Headache; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Temozolomide; Therapeutic Equivalency; Time Factors; Vomiting

2010
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
    British journal of cancer, 2006, Nov-06, Volume: 95, Issue:9

    Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide; Treatment Outcome

2006